Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-04-09
2008-10-14
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S439000, C514S443000
Reexamination Certificate
active
07435834
ABSTRACT:
The present invention relates to compounds of 2-thia-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α(TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
REFERENCES:
patent: 3711489 (1973-01-01), Lombardino
patent: 4145434 (1979-03-01), Van Der Burg
patent: 4198421 (1980-04-01), Cherkofsky et al.
patent: 6511976 (2003-01-01), Andres-Gil et al.
patent: 967573 (1975-05-01), None
patent: 0063525 (1982-10-01), None
patent: 0 125 484 (1984-11-01), None
patent: 0 357 126 (1990-03-01), None
patent: 0 372 455 (1990-06-01), None
patent: 20000310 (2002-02-01), None
patent: WO 96/14320 (1996-05-01), None
patent: WO 96/14321 (1996-05-01), None
patent: WO 97/38991 (1997-10-01), None
patent: WO 99/19317 (1999-04-01), None
patent: WO-01/87890 (2001-11-01), None
patent: WO 01/87890 (2001-11-01), None
patent: WO 2003/084962 (2003-10-01), None
patent: WO 2005/049020 (2005-06-01), None
patent: WO 2005/072728 (2005-08-01), None
Gansser C. et al. “Determination de l'activite radioprotectrice d'analogues de l'imipramine”Ann. Pharm. (1984), 41, 465-471.
Pfeffer et al., Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection, Cell, 1993, 73:457-467.
Elliott et al., Randomoised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis, The Lancet, 1994, 344:1105-1110.
Keffer et al., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, EMBO J., 1991, 10:4025-4031.
Carswell et al., An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670.
Mori et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 1996, 157:3178-3182.
Georgopoulos et al., Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis In Transgenic Mice, J. Imflamm., 1996, 46:86-97.
Dinarello et al., Interleukin-1, Rev. Infect Disease, 1984, 6(1):51-95.
Bresnihan et al., Treatment with Recombinant Human Interleukin-1 Receptor Antagonist (rhIL-1ra) in Rheumatoid Arthritis (RA); Results of a Randomized Double-Blind, Placebo-Controlled Multicenter trial, Arthrit. Rheum., 1996, 39:73.
Dinarello, An Update on Human Interleukin-1: From Molecular Biology to Clinical Relevance, J. Clinical Immunology, 1985, 5:287.
Van Assche and Rutgeerts, Anti-TNF agents in Chrohn's disease., Exp. Opin. Invest. Drugs, 2000, 9:103-111.
Lombardino, Synthesis of Some Novel Tetracyclic Imidazole Derivatives, J Heterocyclic Chem., 1974, 11:17-21.
Menozzi, omega-Dialkylaminoalkyl Ethers of Phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with Analgesic and Anti-inflammatory Activity, J. Heterocyclic Chem., 1997, 34:963-968.
Chadwick et al., Preparation of Thiophen Esters by the Hinsberg Reaction, J. Chem. Soc. Perkin Trans. 1, 1972, 2079-2081.
Leonard et al., The Influence of Steric Configuration on the Ultraviolet Absorption of “Fixed” Benzils, J. Am. Chem. Soc., 1955, 77:5078.
Overberger et al., Cyclic Sulfones. II. The Polymerization of Styrene on the Presence of 3,4-Diphenylthiophene-1-dioxide and 3,4-Di-(p-chlorophenyl)-thiophene-1-dioxide, J. Am. Chem. Soc., 1950, 72:4958-4961.
Badger et al., Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function, J. Pharmac. Env. Therap., 1996, 279:1453-1461.
Fukawa et al., A Method for Evaluating Analgesic Agents in Rats, J. Pharmacol. Meth., 1980, 4:251-259.
Schweizer et al., Combined automated writhing/motility test for testing analgesics, Agents and Actions, 1988, 23:29-31.
Collier et al., The Abdominal Constriction Response and Its Suppression By Analgesic Drugs in the Mouse, Br. J. Pharmac. Chemother., 1968, 32:295-310.
Gansser et al., Determination de l'active radioprotrctrice d'analogues de l'imipramine, Ann. Pharm., 1983, 41(5):465-471.
Schulz et al., Synthese von 1, 3a,3, 12b-Tertrahydro-dibenzo[b,f]-pyrasolo[3,4-d]azepin-Derivaten,Z. Chem, 1988, 25: 181-182.
Funke et al., Physico-chemical Properties and Stability of trans-5-Chloro-2-methyl1-2-3, 3a, 12b-tetrahydro-1h-dibenz[2,3,:6,7]oxepino[4,5-c]pyrrolidine Maleate,Arzeim-Forsch., 1990, 40:536-539.
Bennett et al., Reaction of 5-Acety 1-10, didehydroi-5H-dibenz[b,f] azepine with Pyrrole, N-Methylpyrrole, Imadazolke and N-Methylimidazole: Cycloaddtion Versus Michael Addition,J. Heterocycl. Chem., 1994, 31: 293-296.
Bymaster F., et al. “New Approaches to Developing Antidepressants By Enhancing Monoaminergic Neurotransmission.” Expert Opinion Investig. Drugs, 2003, 12, pp. 531-543.
Spampinato U. et al. “Role of Striata Serotonin 2A and Serotinin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum.” J. Neurochemistry, 2000, vol. 74, pp. 693-701.
Monnet F.P., et al. “N-Methyl-D-Aspartate-Induced Neuronal Activation Is Selectively Modulated by o Receptors.” European Journal of Pharmacology, 1990, vol. 179, pp. 441-445.
Claghorn J., et al. “N-Methyl-D-Aspartate-Induced In Antidepressant Agents.” Progress in Drug Research Clinic Inc., 1996, vol. 46, pp. 243-262.
Sperling W. et al., “New Tetracyclic Antidepressants.” Drugs Today, 1997, vol. 33, No. 2, pp. 95-102.
Andres J.I., et al. “R107500. A New 5-HT 2A/2C Antagonist With Potential Anxiolytic Profile.” Drugs Fut., 2002, vol. 27, Suppl. A:C41.
Cid J.M., et al. “Synthesis Of 2-Aminomethyl-3, 3a, 8, 12.” Drugs Fut., 2002, vol. 27, Suppl. A:P182.
Meert T.F., et al. “Psychopharmacology Of Ritanserin: Comparison With Chlordiazepoxide.” Drug Development Research, 1989, vol. 18, pp. 119-144.
Niemegeers C.J.E., et al. “Interaction Of Drugs With Apomorphine, Tryptamine And Norepinephrine. A New “In Vivo” Approach: The ATN-Test In Rats.” Arch. Int. Pharmacodyn., 1977, vol. 227, pp. 238-253.
Berge S.M., et al. “Pharmaceutical Salts.” Journal of Pharmaceutical Sciences, 1997, vol. 66, pp. 1-20.
Thomson W., et al. Juvenile Idiopathic Arthritis Genetics - What's New? What's Next? Arthritis Research, 2002, vol. 4 and 5, pp. 302-306.
Wolf W.A., et al. “The Serotonin 5-HT 2C Receptor Is A Prominent Serotinin Receptor In Basel Ganglia: Evidence From Functional Studies On Serotonin-Mediated Phosphoinositide Hydrolysis.” Journal of Neurochemistry, 1997, vol. 69, p. 1449.
Porsolt R.D., et al. “Behavioral Despair in Mice: A Primary Screening Test For Antidepressants.” Arch. Int. Pharmacodyn., 1997, vol. 229, pp. 327-336.
Millam M.J., et al. “S18126 ({2-4-2,3-dihydrobenzol(1,4) dioxin-6-yl)piperazin-1-ylmethyl}), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An in vitro and in vivo Comparison with L 745,870 (3-(4-(4-chlorophenyl)piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride.” Journal of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 1, pp. 167-186.
Bonhaus D.W., et al. “The Pharmacology and Distribution of Human 5-hydroxytrptamine 2B (5hT2B) Receptor Gene Products; Comparison With 5-HT2A and 5HT2C Receptors.” British Journal of Pharmacology, 1995, vol. 115, pp. 622-628.
Saucier C., et al. “Identification of An Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Inviolves Decreases in Receptor RNA and Number.” Journal of Neurochemistry, 1997, vol. 68, No. 1, pp. 1998-2011.
Beers M.H., et al. “The Merck Manual of Diagnosis and Therapy, 17thedition.” 1999, Merck Research Labo
Mercep Mladen
Mesic Milan
Ozimec Ivana
Pesic Dijana
GlaxoSmithKline Istrazivacki Center Zagreb D.O.O.
Stockton Laura L.
Young J. Scott
LandOfFree
2-thia-dibenzoazulenes as inhibitors of tumour necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-thia-dibenzoazulenes as inhibitors of tumour necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-thia-dibenzoazulenes as inhibitors of tumour necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001591